Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer.

MLA

Sharma, Saurabh, et al. “Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer.” Advanced Therapeutics, vol. 7, no. 5, May 2024, pp. 1–20. EBSCOhost, https://doi.org/10.1002/adtp.202300388.

APA

Sharma, S., Pradhan, R., Lee, D., Sharma, M., Nasab, S. Z., Hejmady, S., Chander, S., Mohaghegh, N., Maity, S., Khan, S., Khademhosseini, A., & Kirane, A. (2024). Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer. Advanced Therapeutics, 7(5), 1–20. https://doi.org/10.1002/adtp.202300388

Chicago

Sharma, Saurabh, Rajesh Pradhan, David Lee, Mahalaxmi Sharma, Shima Zahed Nasab, Siddhanth Hejmady, Subhash Chander, et al. 2024. “Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer.” Advanced Therapeutics 7 (5): 1–20. doi:10.1002/adtp.202300388.